Senti Bio Releases Mechanism of Action Video for First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202

Core Insights - Senti Biosciences, Inc. is advancing its lead asset, SENTI-202, a first-in-class off-the-shelf CAR NK cell therapy targeting hematologic malignancies like AML and MDS [2][3] - The company has reported positive preliminary results from a Phase 1 clinical trial, indicating SENTI-202 is well-tolerated with no dose-limiting toxicities [4] - The mechanism of action for SENTI-202 involves a novel gene circuit that selectively kills leukemia cells while sparing healthy hematopoietic stem cells [3][8] Company Overview - Senti Bio is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [2][6] - The company's pipeline includes engineered cell therapies targeting both liquid and solid tumors, leveraging synthetic biology for enhanced precision and control [6] Clinical Trial Details - SENTI-202 is currently in a Phase 1 trial enrolling adult patients with relapsed/refractory CD33 and/or FLT3-expressing hematologic malignancies [3] - The preliminary recommended Phase 2 dose (RP2D) for SENTI-202 was identified as 1.5 x 10 CAR NK cells administered on Days 0, 7, and 14 in 28-day cycles following lymphodepleting chemotherapy [4] - In the preliminary RP2D cohort, 2 of 3 patients achieved a composite Complete Remission (cCR), and 5 of 7 evaluable patients achieved an overall response rate (ORR) [4] Mechanism of Action - SENTI-202 utilizes a Logic Gated gene circuit to activate CAR targeting CD33 and/or FLT3, which are expressed in approximately 95% of AML patients [8] - The therapy protects healthy hematopoietic stem and progenitor cells (HSC/HSPCs) from off-tumor effects through an inhibitory CAR targeting Endomucin (EMCN) [8]